Congratulations to Dr. Oren Moscovitz from the Scojen Institute of Synthetic Biology, Reichman University for winning a research grant from MOST-DGF, a joint funding program between Israel's Ministry of Science and the German Research Foundation, which aims to encourage research collaborations between Israeli and German researchers.
This research aims to develop an innovative treatment for triple negative breast cancer (TNBC), one of the most aggressive forms of breast cancer with high mortality rates and limited treatment options.
Based on recently published work, Oren and his group discovered an innovative method for engineering antibodies that allows antibodies to target different types of blood and breast cancers with high specificity.
The method, which was also effectively demonstrated in a mouse model, gives antibodies the ability to simultaneously target two types of cancer cells, thus bypassing the genetic changes that cancer cells use to prevent recognition by antibodies and thus becoming for treatment-resistant.
The new grant is intended to deepen knowledge about the mechanism of action of the engineered antibodies and to test their safety, with the aim of expanding the limited toolbox in the fight against triple-negative breast cancer.
The study was conducted in collaboration with Dr. Christian Seitz from the HOPP Children's Cancer Hospital, Heidelberg, Germany.